Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Sepsis patients were divided into no AKI, mild AKI, and severe AKI groups according to RIFLE criteria. 29682165 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Secondary end points included any myocardial ischemia, respiratory and early procedural complications, acute kidney injury (AKI) according to RIFLE criteria (Risk, Injury, Failure, Loss of kidney function, and End-stage renal failure), spinal cord ischemia, a composite of these complications, and postoperative intensive care unit length of stay. 29576405 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE The main outcomes were severe infusion-related adverse events according to the Common Terminology Criteria for Adverse Events and the renal failure category of RIFLE criteria for acute kidney injury (AKI) during treatment. 29038262 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE The impact of AKI and renal failure (using RIFLE score) in 1-year mortality was analysed, along with other confounding variables. 29501603 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE According to RIFLE criteria; AKI-Risk, AKI-Injury and AKI-Failure occurred in 26 (2.6%), 9 (0.9%) and 11 (1.1%) patients, respectively. 29757568 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE AKI was defined according to the RIFLE criteria (risk, injury, failure, loss of kidney function, and end-stage kidney disease): increase by 50% in sCr or reduction of at least 25% of estimated glomerular filtration rate (eGFR) from baseline. 29472806 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE The RIFLE classification was used to assess the severity of acute kidney injury (AKI). 30217302 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE We then compared KeGFR with the current standard Acute Kidney Injury Network (AKIN criteria) and Risk Injury Failure Loss End-Stage Kidney Disease (RIFLE criteria) and new criteria (Waikar-Bonventre, Delta check) for AKI detection. 30231255 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Acute kidney injury (AKI) during the first 7 days was evaluated based on the RIFLE criteria. 29118769 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Outcomes included acute kidney injury (AKI) defined by RIFLE and changes in serum creatinine (sCr), eGFR, and chronic kidney disease (CKD) staging up to 5 years. 28285957 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE A total of 119 children of INS (age: 2-18 years) fulfilling the pediatric RIFLE criteria for the diagnosis of AKI were enrolled and followed up for 3 months to determine the outcome. 28093933 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Safety was assessed using incidence of acute kidney injury (AKI) based on RIFLE (risk, injury, failure, loss, end-stage renal disease) criteria. 27139010 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Primary endpoint was AKI following the creatinine based RIFLE classification. 29045467 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE AKI was defined as a 1.5-fold increase in serum creatinine per RIFLE criteria. 29872606 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE However, postoperative AKI (assessed by 2 criteria) occurred more frequently in group HES than in group NoHES (by KDIGO criteria: 10.7% vs. 3.6%; OR 3.43 [95% CI, 1.67-7.04]; P < .001 and by RIFLE criteria: 9.6% vs. 2%; OR 3.32 [95% CI, 1.34-8.24]; P = .01). 28471979 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE The adoption of diagnostic criteria for AKI (RIFLE, AKIN and KDIGO) has facilitated comparison of data reported by different centres, confirming that even mild AKI is associated with excess mortality. 27803367 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Three hundred thirty nine patients were included; AKI developed in 141 (41.6%) patients; RISK in 27 (8%) patients; INJURY in 25 (7%); FAILURE in 89 (26%) by the RIFLE criteria. 28143505 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Urine output criteria detected AKI in patients without AKI at ICU admission in a median of 13 h (IQR 7-22 h; using RIFLE definition) after admission compared to a median of 24 h using serum creatinine criteria (IQR24-48 h). 28219327 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE This study evaluated the incidence, predictors and prognosis of AKI associated with scrub typhus according to the RIFLE (risk, injury, failure, loss, end-stage kidney disease) criteria. 28298367 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Using RIFLE criteria, 6 patients in the control group and 2 patients in the nicardipine group were classified as having acute kidney injury. 27231835 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE After suprarenal clamping, 2 retrospective studies used the RIFLE criteria to define the incidence of AKI, and the pooled AKI rate was 36.8%. 27890835 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE AKI was defined and graded using either the modified RIFLE criteria or the Pediatrics RIFLE criteria, while CKD was graded using the KDIGO criteria. 29212494 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Of 380 children, 53 children (14%) had AKI (met any of the RIFLE criteria). 26752169 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Group I also manifested significantly higher incidence of AKI than group II (62.7% vs. 28.5%, p = 0.005), even when stratified according to RIFLE criteria ('Risk' 33.9% vs. 10.7%; 'Injury' 10.2% vs. 8.9%; 'Failure' 18.6% vs. 8.9%; p = 0.03). 28353411 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Prevalence of AKI based on RIFLE criteria was 60% and 15% in high dose and conventional dose groups, respectively (P = 0.003). 28979332 2017